<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Breast Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Breast Cancer</journal-id><journal-title-group><journal-title>Breast Cancer (Tokyo, Japan)</journal-title></journal-title-group><issn pub-type="ppub">1340-6868</issn><issn pub-type="epub">1880-4233</issn><publisher><publisher-name>Springer Japan</publisher-name><publisher-loc>Tokyo</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31372841</article-id><article-id pub-id-type="pmc">6954153</article-id><article-id pub-id-type="publisher-id">999</article-id><article-id pub-id-type="doi">10.1007/s12282-019-00999-8</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>High expression of soluble CD155 in estrogen receptor-negative breast cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Iguchi-Manaka</surname><given-names>Akiko</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Okumura</surname><given-names>Genki</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Ichioka</surname><given-names>Emika</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kiyomatsu</surname><given-names>Hiroko</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Ikeda</surname><given-names>Tatsuhiko</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Bando</surname><given-names>Hiroko</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Shibuya</surname><given-names>Akira</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Shibuya</surname><given-names>Kazuko</given-names></name><address><email>kazukos@md.tsukuba.ac.jp</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.20515.33</institution-id><institution-id institution-id-type="ISNI">0000 0001 2369 4728</institution-id><institution>Department of Breast and Endocrine Surgery, Faculty of Medicine, </institution><institution>University of Tsukuba, </institution></institution-wrap>Tsukuba, 305-8575 Japan </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.20515.33</institution-id><institution-id institution-id-type="ISNI">0000 0001 2369 4728</institution-id><institution>Department of Immunology, Faculty of Medicine, </institution><institution>University of Tsukuba, </institution></institution-wrap>Tsukuba, 305-8575 Japan </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.20515.33</institution-id><institution-id institution-id-type="ISNI">0000 0001 2369 4728</institution-id><institution>Life Science Center for Survival Dynamics, Tsukuba Advanced Research Alliance (TARA), University of Tsukuba, </institution></institution-wrap>Tsukuba, 305-8575 Japan </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.412814.a</institution-id><institution-id institution-id-type="ISNI">0000 0004 0619 0044</institution-id><institution>Department of Breast and Endocrine Surgery, </institution><institution>University of Tsukuba Hospital, </institution></institution-wrap>Tsukuba, 305-8576 Japan </aff></contrib-group><pub-date pub-type="epub"><day>1</day><month>8</month><year>2019</year></pub-date><pub-date pub-type="pmc-release"><day>1</day><month>8</month><year>2019</year></pub-date><pub-date pub-type="ppub"><year>2020</year></pub-date><volume>27</volume><issue>1</issue><fpage>92</fpage><lpage>99</lpage><history><date date-type="received"><day>12</day><month>3</month><year>2019</year></date><date date-type="accepted"><day>26</day><month>7</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2019</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">The poliovirus receptor (CD155) is expressed ubiquitously at low levels on both hematopoietic and nonhematopoietic cells, but its expression is upregulated in various tumor cells. An activating receptor DNAM-1 expressed on cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells binds to CD155 and mediates the cytotoxic activity of CTLs and NK cells against tumors. Unlike mouse tissues, human tissues express a soluble form of CD155 (sCD155), which is a splicing isoform of CD155 lacking the transmembrane region. We previously reported that the serum levels of sCD155 were higher in lung, gastrointestinal, breast, and gynecologic cancer patients than in healthy donors. Here, we focus on breast cancer patients.</p></sec><sec><title>Methods</title><p id="Par2">To analyze the association between serum level of sCD155 and clinicopathological parameters of breast cancer, we quantified sCD155 in the sera of 153 breast cancer patients by sandwich ELISA.</p></sec><sec><title>Results</title><p id="Par3">sCD155 levels in the sera of breast cancer patients were positively correlated with patient age, disease stage, and invasive tumor size. Moreover, they were higher in patients with estrogen receptor (ER)-negative cancers than in those with ER-positive tumors, and higher in those with Ki-67-high cancers than in those with Ki-67-low cancers.</p></sec><sec><title>Conclusions</title><p id="Par4">The serum level of sCD155 is correlated with high risk factors in breast cancer.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Soluble CD155</kwd><kwd>DNAM-1</kwd><kwd>ER-negative</kwd><kwd>Ki-67-high</kwd></kwd-group><funding-group><award-group><funding-source><institution>KAKENHI</institution></funding-source><award-id>JP26861038</award-id><award-id>JP17K10533</award-id><award-id>JP15H01365</award-id><award-id>JP16H06387</award-id><award-id>JP16H05169</award-id><principal-award-recipient><name><surname>Iguchi-Manaka</surname><given-names>Akiko</given-names></name><name><surname>Shibuya</surname><given-names>Akira</given-names></name><name><surname>Shibuya</surname><given-names>Kazuko</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Japanese Breast Cancer Society 2020</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">The interactions between the immune system and cancer are complicated, because the immune system plays dual roles of cancer suppression and promotion [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells play key roles in tumor suppression by mediating tumor recognition and activation through their antigen receptors and a variety of adhesion and costimulatory molecules [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. Interactions between cell surface receptors on CTLs and NK cells and their ligands expressed on tumor cells induce cytotoxic activity against tumor cells [<xref ref-type="bibr" rid="CR5">5</xref>].</p><p id="Par6">DNAM-1 (CD226) is a member of the immunoglobulin superfamily and is expressed on NK cells, T cells, monocytes, macrophages, and platelets [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. Its ligands in humans and mice are CD155 (also called poliovirus receptor [PVR]) and its family member CD112 (also called PVR-related family 2 [PRR-2] or nectin-2) [<xref ref-type="bibr" rid="CR8">8</xref>&#x02013;<xref ref-type="bibr" rid="CR10">10</xref>]. Human CD155 and CD112 are broadly distributed on epithelial and endothelial cells as well as hematopoietic cells and are overexpressed on various tumors [<xref ref-type="bibr" rid="CR11">11</xref>&#x02013;<xref ref-type="bibr" rid="CR15">15</xref>]. Interactions between DNAM-1 on CTLs and NK cells and CD155 and CD112 on tumor cells augment the cytotoxicity of these cells against tumors [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. Chemical carcinogen-induced tumor models using DNAM-1-deficient mice have shown that DNAM-1 plays an important role in immune surveillance against CD155-expressing tumors [<xref ref-type="bibr" rid="CR16">16</xref>].</p><p id="Par7">Unlike mouse tissues, which express membrane-bound CD155 (mCD155), human tissues also express soluble CD155 (sCD155) encoded by splicing isoforms of CD155 (CD155&#x003b2; and CD155&#x003b3;) that lack exon 6 encoding the transmembrane region [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. We previously reported that serum levels of sCD155 were higher in patients with various cancer types (lung, gastrointestinal, breast, and gynecologic) than in healthy donors. Moreover, they were higher in patients with advanced-stage gastric cancer compared with an early stage of the cancer [<xref ref-type="bibr" rid="CR19">19</xref>].</p><p id="Par8">In recent years, diagnosis and therapy for breast cancer have made remarkable progress on the basis of biological research. In 2000, intrinsic subtypes of breast cancer were identified according to gene-expression patterns [<xref ref-type="bibr" rid="CR20">20</xref>]. Breast cancers were then classified into five subtypes based on the expression levels of estrogen receptor (ER), progesterone receptor (PgR), human epidermal growth factor receptor 2 (HER2), and Ki-67 in tumor cells, as determined by immunohistochemical and gene-expression analyses (St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011) [<xref ref-type="bibr" rid="CR21">21</xref>]. These subtypes exhibit different epidemiologies, natural histories, and responses to therapies [<xref ref-type="bibr" rid="CR21">21</xref>]. Therefore, characterization of the intrinsic subtypes of breast cancer is important for the development of appropriate therapies.</p><p id="Par9">Here, we analyzed the association between serum levels of sCD155 and the clinicohistopathological features of a cohort of 153 breast cancer patients.</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Samples</title><p id="Par10">Serum samples were obtained from patients admitted to the University of Tsukuba Hospital, Japan, for primary treatment of breast cancer. Cases of multiple, bilateral breast cancers or multiple primary cancers were excluded from this study. Patients who received neoadjuvant therapy were also excluded. Written informed consent was obtained from all individual participants included in the study. The study was approved by the ethics committee of the University of Tsukuba (approval number, 531-5). Disease stage was classified according to The Union for International Cancer Control (UICC) TNM Classification of Malignant Tumors. Surgically treated cases were classified pathologically, and other cases were classified clinically. ER and PgR statuses were evaluated by immunostaining. Human epidermal growth factor receptor 2 (HER2) status was evaluated by immunostaining, and in cases with a score of 2+, it was evaluated by fluorescence in situ hybridization. Cases of ductal carcinoma in situ were not included in the analyses of nuclear grade; ER, PgR, and HER2 statuses; or Ki-67 index.</p></sec><sec id="Sec4"><title>ELISA for human soluble CD155</title><p id="Par11">In brief, Nunc-Immuno Plates (Thermo Fisher Scientific, MA) were coated with anti-CD155 antibody (D171 [Thermo Fisher Scientific, MA], 0.2&#x000a0;&#x000b5;g/mL in carbonate-bicarbonate buffer, pH 9.3&#x02013;9.9 [Sigma-Aldrich, MO], 100 &#x000b5;L/well) for capture for 1&#x000a0;h at room temperature (RT), washed three times with washing buffer (PBS containing 0.05% TWEEN 20 [Sigma-Aldrich, MO]), and treated with blocking buffer (washing buffer containing 0.5% bovine serum albumin fraction V [Roche, Switzerland]) for 1&#x000a0;h at RT. After the plates had been washed again, human chimeric protein consisting of the extracellular portion of CD155&#x003b2; fused with Flag peptide at the C-terminus (CD155&#x003b2;-FLAG) (as a standard; provided by Chugai Pharmaceutical Co., Ltd., Japan) and serum samples of patients (1:100 in blocking buffer) or control pooled sera (Biopredic International, France, Human True A serum, pool of donors, 1:100 in blocking buffer) were plated at 100 &#x000b5;L/well, incubated for 1&#x000a0;h at RT, washed, and then incubated with anti-Cynomolgus monkey PVR antibody (Sino Biological, China, 0.2&#x000a0;&#x000b5;g/mL in blocking buffer, 100 &#x000b5;L/well). This was followed by treatment with biotinylated monoclonal anti-rabbit IgG (&#x003b3;-chain specific) antibody (Sigma-Aldrich, MO, 1:5000 in blocking buffer, 100 &#x000b5;L/well). The plates were then incubated with Streptavidin-Poly HRP 80 (SDT, 1:5000 in blocking buffer, 100 &#x000b5;L/well). This was followed by reaction with 100 &#x000b5;L of TMB One Component HRP Microwell Substrate (BioFX Laboratories, MD) for 5&#x000a0;min at RT. The reactions were stopped with 50 &#x000b5;L of 0.5&#x000a0;mol/L sulfuric acid, and the absorbance of each well at a wavelength of 450&#x000a0;nm was measured with a Spectra Max M2e reader (Molecular Devices, CA). All values were determined in triplicate.</p></sec><sec id="Sec5"><title>CD155 expression analysis using The Cancer Genome Atlas open access data</title><p id="Par12">RNA expression data of CD155&#x003b1; and CD155&#x003b3; in normal and cancerous breast tissues were extracted from The Cancer Genome Atlas (TCGA) open access data in January 2014 (<ext-link ext-link-type="uri" xlink:href="https://tcga-data.nci.nih.gov/docs/publications/tcga/">https://tcga-data.nci.nih.gov/docs/publications/tcga/</ext-link>). For both CD155&#x003b1; and CD155&#x003b3;, expression ratios of cancer tissue versus normal tissue were calculated using the following formula: CD155&#x003b1; or &#x003b3; expression ratio&#x02009;=&#x02009;read counts of CD155&#x003b1; or &#x003b3;-specific junction (CD155 Exon 6b-7) in cancer tissue/read counts of CD155&#x003b1; &#x003b3;-specific junctions in paired normal tissue.</p></sec><sec id="Sec6"><title>Statistics</title><p id="Par13">Statistical analyses were performed using Spearman rank-order correlation and the two-tailed Mann&#x02013;Whitney <italic>U</italic> test. All analyses were performed with GraphPad Prism (GraphPad Software, CA). <italic>P</italic> values less than 0.05 were considered to be statistically significant.</p></sec></sec><sec id="Sec7"><title>Results</title><sec id="Sec8"><title>Correlation between clinicopathological parameters and serum levels of sCD155 in breast cancer patients</title><p id="Par14">To analyze the association between serum level of sCD155 and clinicopathological parameters of breast cancer, we quantified sCD155 in the sera of 153 breast cancer patients before primary treatment by sandwich ELISA. Of these patients, 149 were treated surgically and their pathological parameters were determined by pathohistological analysis of the surgical specimen. The other 4 patients, who were all at stage 4, were treated without surgery; their clinicopathological parameters were determined by imaging diagnosis and core needle biopsy of the primary tumor. sCD155 levels in the sera of the 153 breast cancer patients were significantly positively correlated with patient age, disease stage, and tumor size (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>, Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>a). Furthermore, the levels were significantly higher in patients with ER-negative versus ER-positive cancers and in patients with high versus low Ki-67 cancers (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>, Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>b). As a reference, the median level of sCD155 in the purchased pooled sera of 26 healthy donors (Biopredic International) was 289.96&#x000a0;ng/mL, which was lower than the median of ER-positive and low Ki-67 cancers. These results suggest that serum levels of sCD155 are associated with the clinicopathological characteristics of breast cancer patients.<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Clinicopathological parameters and serum levels of sCD155 in breast cancer patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Clinicopathological parameter</th><th align="left" rowspan="2">Number (%)</th><th align="left" colspan="4">sCD155 (ng/mL)</th></tr><tr><th align="left">Mean</th><th align="left">Median</th><th align="left">Range</th><th align="left">Significance</th></tr></thead><tbody><tr><td align="left">Age (years)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;36&#x02013;39</td><td align="left">12 (7.8)</td><td align="left">339.6</td><td align="left">338.5</td><td align="left">162.5&#x02013;610.4</td><td align="left"><italic>r</italic><sub><italic>s</italic></sub>&#x02009;=&#x02009;0.26</td></tr><tr><td align="left">&#x000a0;40&#x02013;49</td><td align="left">44 (28.8)</td><td align="left">309.6</td><td align="left">311.0</td><td align="left">139.8&#x02013;586.1</td><td align="left"><italic>P&#x02009;</italic>&#x0003c;&#x02009;0.01*</td></tr><tr><td align="left">&#x000a0;50&#x02013;59</td><td align="left">41 (26.8)</td><td align="left">332.5</td><td align="left">307.4</td><td align="left">144.8&#x02013;795.3</td><td align="left"/></tr><tr><td align="left">&#x000a0;60&#x02013;88</td><td align="left">56 (36.6)</td><td align="left">373.3</td><td align="left">356.7</td><td align="left">192.6&#x02013;623.9</td><td align="left"/></tr><tr><td align="left">Treatment</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Surgery</td><td align="left">149</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Other</td><td align="left">4</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Histological type</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Ductal carcinoma in situ</td><td align="left">16 (10.5)</td><td align="left">276.2</td><td align="left">280.7</td><td align="left">139.8&#x02013;376.0</td><td align="left"/></tr><tr><td align="left">&#x000a0;Invasive carcinoma of NST</td><td align="left">118 (77.1)</td><td align="left">354.1</td><td align="left">330</td><td align="left">144.8&#x02013;795.3</td><td align="left"/></tr><tr><td align="left">&#x000a0;Invasive lobular carcinoma</td><td align="left">14 (9.2)</td><td align="left">318.6</td><td align="left">325</td><td align="left">188.7&#x02013;482.9</td><td align="left"/></tr><tr><td align="left">&#x000a0;Invasive micropapillary carcinoma</td><td align="left">2 (1.3)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Apocrine carcinoma</td><td align="left">2 (1.3)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Mucinous carcinoma</td><td align="left">1 (0.7)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Stage</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;0</td><td align="left">16 (10.5)</td><td align="left">276.2</td><td align="left">280.7</td><td align="left">139.8&#x02013;376.0</td><td align="left"><italic>r</italic><sub><italic>s</italic></sub>&#x02009;=&#x02009;0.23</td></tr><tr><td align="left">&#x000a0;1</td><td align="left">56 (36.6)</td><td align="left">328.9</td><td align="left">314.4</td><td align="left">144.8&#x02013;630.6</td><td align="left"><italic>P&#x02009;</italic>&#x0003c;&#x02009;0.01*</td></tr><tr><td align="left">&#x000a0;2</td><td align="left">59 (38.6)</td><td align="left">355</td><td align="left">325.7</td><td align="left">153.7&#x02013;623.9</td><td align="left"/></tr><tr><td align="left">&#x000a0;3&#x02013;4</td><td align="left">22 (14.4)</td><td align="left">384.2</td><td align="left">353.9</td><td align="left">188.7&#x02013;795.3</td><td align="left"/></tr><tr><td align="left">Size of invasive tumor (cm)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;0.0&#x02013;2.0</td><td align="left">96 (62.7)</td><td align="left">320.1</td><td align="left">310.9</td><td align="left">139.8&#x02013;630.6</td><td align="left"><italic>r</italic><sub><italic>s</italic></sub>&#x02009;=&#x02009;0.23</td></tr><tr><td align="left">&#x000a0;2.1&#x02013;5.0</td><td align="left">41 (26.8)</td><td align="left">367.7</td><td align="left">334.3</td><td align="left">153.7&#x02013;623.9</td><td align="left"><italic>P&#x02009;</italic>&#x0003c;&#x02009;0.01*</td></tr><tr><td align="left">&#x000a0;&#x02265;&#x02009;5.1</td><td align="left">11 (7.2)</td><td align="left">360.1</td><td align="left">356.9</td><td align="left">188.7&#x02013;532.2</td><td align="left"/></tr><tr><td align="left">&#x000a0;Unknown</td><td align="left">5 (3.3)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Lymph node metastasis</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Negative</td><td align="left">94 (61.4)</td><td align="left">328.5</td><td align="left">321.3</td><td align="left">139.8&#x02013;630.6</td><td align="left"><italic>P&#x02009;</italic>=&#x02009;0.14<sup>a</sup></td></tr><tr><td align="left">&#x000a0;Positive</td><td align="left">59 (38.6)</td><td align="left">362</td><td align="left">334.3</td><td align="left">153.7&#x02013;795.3</td><td align="left"/></tr><tr><td align="left">Vascular invasion</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Negative</td><td align="left">102 (66.7)</td><td align="left">337.9</td><td align="left">328.2</td><td align="left">139.8&#x02013;630.6</td><td align="left"><italic>P&#x02009;</italic>=&#x02009;0.91<sup>a</sup></td></tr><tr><td align="left">&#x000a0;Positive</td><td align="left">40 (26.1)</td><td align="left">338.4</td><td align="left">323.8</td><td align="left">153.7&#x02013;614.6</td><td align="left"/></tr><tr><td align="left">&#x000a0;Unknown</td><td align="left">11 (7.2)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Nuclear grade (except for DCIS)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;1</td><td align="left">59 (43.1)</td><td align="left">333.6</td><td align="left">310.8</td><td align="left">144.8&#x02013;556.6</td><td align="left"><italic>r</italic><sub><italic>s</italic></sub>=&#x02009;0.17</td></tr><tr><td align="left">&#x000a0;2</td><td align="left">31 (22.6)</td><td align="left">332.1</td><td align="left">306</td><td align="left">161.4&#x02013;623.9</td><td align="left"><italic>P&#x02009;</italic>=&#x02009;0.055</td></tr><tr><td align="left">&#x000a0;3</td><td align="left">36 (26.3)</td><td align="left">390.3</td><td align="left">352.3</td><td align="left">153.7&#x02013;795.3</td><td align="left"/></tr><tr><td align="left">&#x000a0;Unknown</td><td align="left">11 (8.0)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">ER status (except for DCIS)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Negative</td><td align="left">18 (13.1)</td><td align="left">398.7</td><td align="left">352.4</td><td align="left">291.8&#x02013;795.3</td><td align="left"><italic>P&#x02009;</italic>&#x0003c;&#x02009;0.05*<sup>a</sup></td></tr><tr><td align="left">&#x000a0;Positive</td><td align="left">119 (86.9)</td><td align="left">341.5</td><td align="left">321.9</td><td align="left">144.8&#x02013;630.6</td><td align="left"/></tr><tr><td align="left">PgR status (except for DCIS)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Negative</td><td align="left">25 (18.2)</td><td align="left">378.7</td><td align="left">351.3</td><td align="left">239.7&#x02013;795.3</td><td align="left"><italic>P&#x02009;</italic>=&#x02009;0.14<sup>a</sup></td></tr><tr><td align="left">&#x000a0;Positive</td><td align="left">112 (81.8)</td><td align="left">342.4</td><td align="left">322.6</td><td align="left">144.8&#x02013;630.6</td><td align="left"/></tr><tr><td align="left">HER2 status (except for DCIS)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Negative</td><td align="left">123 (89.8)</td><td align="left">341.5</td><td align="left">325.7</td><td align="left">144.8&#x02013;630.6</td><td align="left"><italic>P&#x02009;</italic>=&#x02009;0.13<sup>a</sup></td></tr><tr><td align="left">&#x000a0;Positive</td><td align="left">14 (10.2)</td><td align="left">415</td><td align="left">368</td><td align="left">153.7&#x02013;795.3</td><td align="left"/></tr><tr><td align="left">Ki-67 (except for DCIS)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Low (0&#x02013;19%)</td><td align="left">69 (50.4)</td><td align="left">338.1</td><td align="left">324.7</td><td align="left">144.8&#x02013;623.9</td><td align="left"><italic>P&#x02009;</italic>&#x0003c;&#x02009;0.05*<sup>a</sup></td></tr><tr><td align="left">&#x000a0;High (20&#x02013;100%)</td><td align="left">51 (37.2)</td><td align="left">382</td><td align="left">354</td><td align="left">192.6&#x02013;630.6</td><td align="left"/></tr><tr><td align="left">&#x000a0;Unknown</td><td align="left">17 (12.4)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr></tbody></table><table-wrap-foot><p><italic>sCD155</italic> soluble CD155, <italic>r</italic><sub><italic>s</italic></sub> Spearman rank-order correlation, <italic>NST</italic> no special type, <italic>DCIS</italic> ductal carcinoma in situ, <italic>ER</italic> estrogen receptor, <italic>PgR</italic> progesterone receptor, <italic>HER2</italic> human epidermal growth factor receptor 2</p><p>*Significant <italic>P</italic> values</p><p><sup>a</sup>Mann&#x02013;Whitney <italic>U</italic> test</p></table-wrap-foot></table-wrap><fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Correlation between clinicopathological parameters and serum levels of sCD155 in breast cancer patients. <bold>a</bold> Scatter plot, regression line, and correlation coefficient between clinicopathological parameters and serum levels of sCD155. <bold>b</bold> Comparisons of serum levels of sCD155 in patients grouped by the indicated pathological parameters. <italic>r</italic><sub><italic>s</italic></sub> Spearman rank-order correlation, <italic>NG</italic> nuclear grade, <italic>N</italic> lymph node metastasis, <italic>nega</italic> negative, <italic>posi</italic> positive, <italic>VI</italic> vascular invasion, <italic>ER</italic> estrogen receptor, <italic>PgR</italic> progesterone receptor, <italic>HER2</italic> human epidermal growth factor receptor 2</p></caption><graphic xlink:href="12282_2019_999_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec9"><title>Expression analysis of CD155&#x003b1; and CD155&#x003b3; mRNA in breast cancer</title><p id="Par15">Next, for <italic>CD155</italic>&#x003b1; and <italic>CD155</italic>&#x003b3;, we calculated the ratios of mRNA levels in breast cancer tissues versus normal breast tissues of 109 patients using TCGA open access data. We found a significant positive correlation between the expression ratios of <italic>CD155</italic>&#x003b1; and <italic>CD155</italic>&#x003b3; mRNA (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>a). The expression ratios of <italic>CD155</italic>&#x003b1; were significantly higher in ER-negative and PgR-negative breast cancers than in ER-positive and PgR-positive breast cancers, respectively (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>, Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>b). However, the expression ratio of <italic>CD155</italic>&#x003b3; was only significantly higher in ER-negative cancers than in ER-positive cancers (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>, Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>b). There was no correlation between both <italic>CD155</italic>&#x003b1; and <italic>CD155</italic>&#x003b3; expression and disease stage, and there was no significant difference between both <italic>CD155</italic>&#x003b1; and <italic>CD155</italic>&#x003b3; expression and lymph node metastasis state (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>, Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>b).<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Correlation between pathological parameters and CD155 expression in breast cancers in TCGA data. <bold>a</bold> Correlation between expression ratios (cancer/normal) of <italic>CD155</italic>&#x003b1; and <italic>CD155</italic>&#x003b3;. <bold>b</bold> Comparisons between <italic>CD155</italic>&#x003b3; expression ratio in patients grouped by the indicated pathological parameters. <italic>N</italic> lymph node metastasis, <italic>nega</italic> negative, <italic>posi</italic> positive, <italic>ER</italic> estrogen receptor, <italic>PgR</italic> progesterone receptor, <italic>HER2</italic> human epidermal growth factor receptor 2, <italic>r</italic><sub><italic>s</italic></sub> Spearman rank-order correlation</p></caption><graphic xlink:href="12282_2019_999_Fig2_HTML" id="MO2"/></fig><table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Clinicopathological parameters and CD155 expression of breast cancers in TCGA open access data</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Clinicopathological parameter</th><th align="left" rowspan="2">Number (%)</th><th align="left" colspan="4">CD155&#x003b1; expression ratio</th><th align="left" colspan="4">CD155&#x003b3; expression ratio</th></tr><tr><th align="left">Mean</th><th align="left">Median</th><th align="left">Range</th><th align="left">Significance</th><th align="left">Mean</th><th align="left">Median</th><th align="left">Range</th><th align="left">Significance</th></tr></thead><tbody><tr><td align="left">Age (years)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;30&#x02013;39</td><td char="(" align="char">9 (8.3)</td><td char="." align="char">1.847</td><td char="." align="char">1.449</td><td align="left">0.426&#x02013;4.738</td><td align="left"><italic>r</italic><sub><italic>s</italic></sub>=&#x02212;&#x02009;0.060</td><td char="." align="char">1.712</td><td char="." align="char">0.738</td><td align="left">0&#x02013;5.661</td><td align="left"><italic>r</italic><sub><italic>s</italic></sub>=&#x02212;&#x02009;0.008</td></tr><tr><td align="left">&#x000a0;40&#x02013;49</td><td char="(" align="char">30 (27.5)</td><td char="." align="char">0.88</td><td char="." align="char">0.932</td><td align="left">0.000&#x02013;2.206</td><td align="left"><italic>P&#x02009;</italic>=0.538</td><td char="." align="char">0.756</td><td char="." align="char">0.310</td><td align="left">0&#x02013;5.104</td><td align="left"><italic>P&#x02009;</italic>=&#x02009;0.933</td></tr><tr><td align="left">&#x000a0;50&#x02013;59</td><td char="(" align="char">25 (22.9)</td><td char="." align="char">1.049</td><td char="." align="char">1.008</td><td align="left">0.000&#x02013;3.284</td><td align="left"/><td char="." align="char">0.775</td><td char="." align="char">0.466</td><td align="left">0&#x02013;3.789</td><td align="left"/></tr><tr><td align="left">&#x000a0;60&#x02013;90</td><td char="(" align="char">45 (41.3)</td><td char="." align="char">1.038</td><td char="." align="char">0.845</td><td align="left">0.000&#x02013;4.259</td><td align="left"/><td char="." align="char">1.281</td><td char="." align="char">0.484</td><td align="left">0&#x02013;12.319</td><td align="left"/></tr><tr><td align="left">Histological type</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Infiltrating ductal carcinoma</td><td char="(" align="char">94 (86.2)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Mixed</td><td char="(" align="char">10 (9.2)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Medullary carcinoma</td><td char="(" align="char">2 (1.8)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Mucinous carcinoma</td><td char="(" align="char">1 (0.9)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Other</td><td char="(" align="char">2 (1.8)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Stage</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;1</td><td char="(" align="char">19 (17.4)</td><td char="." align="char">0.909</td><td char="." align="char">0.949</td><td align="left">0.000&#x02013;2.525</td><td align="left"><italic>r</italic><sub><italic>s</italic></sub>=&#x02009;&#x02212;&#x02009;0.015</td><td char="." align="char">1.087</td><td char="." align="char">0.484</td><td align="left">0&#x02013;5.104</td><td align="left"><italic>r</italic><sub><italic>s</italic></sub>=&#x02009;0.025</td></tr><tr><td align="left">&#x000a0;2</td><td char="(" align="char">62 (56.9)</td><td char="." align="char">1.12</td><td char="." align="char">0.995</td><td align="left">0.000&#x02013;4.259</td><td align="left"><italic>P&#x02009;</italic>=&#x02009;0.89</td><td char="." align="char">1.037</td><td char="." align="char">0.291</td><td align="left">0&#x02013;12.319</td><td align="left"><italic>P&#x02009;</italic>=&#x02009;0.79</td></tr><tr><td align="left">&#x000a0;3&#x02013;4</td><td char="(" align="char">28 (25.7)</td><td char="." align="char">1.046</td><td char="." align="char">0.724</td><td align="left">0.000&#x02013;4.738</td><td align="left"/><td char="." align="char">1.077</td><td char="." align="char">0.459</td><td align="left">0&#x02013;6.236</td><td align="left"/></tr><tr><td align="left">Lymph node metastasis</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Negative</td><td char="(" align="char">41 (37.6)</td><td char="." align="char">0.998</td><td char="." align="char">0.949</td><td align="left">0.000&#x02013;2.830</td><td align="left"><italic>P&#x02009;</italic>=&#x02009;0.90<sup>a</sup></td><td char="." align="char">0.979</td><td char="." align="char">0.203</td><td align="left">0&#x02013;5.104</td><td align="left"><italic>P&#x02009;</italic>=&#x02009;0.73<sup>a</sup></td></tr><tr><td align="left">&#x000a0;Positive</td><td char="(" align="char">65 (59.6)</td><td char="." align="char">1.109</td><td char="." align="char">0.929</td><td align="left">0.000&#x02013;4.738</td><td align="left"/><td char="." align="char">1.125</td><td char="." align="char">0.508</td><td align="left">0&#x02013;12.319</td><td align="left"/></tr><tr><td align="left">&#x000a0;Unknown</td><td char="(" align="char">3 (2.8)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">ER status by IHC</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Negative</td><td char="(" align="char">19 (17.4)</td><td char="." align="char">1.987</td><td char="." align="char">1.614</td><td align="left">0.000&#x02013;4.738</td><td align="left"><italic>P&#x02009;</italic>&#x0003c;0.0001*<sup>a</sup></td><td char="." align="char">2.039</td><td char="." align="char">1.415</td><td align="left">0&#x02013;12.319</td><td align="left"><italic>P&#x02009;</italic>&#x0003c;&#x02009;0.01*<sup>a</sup></td></tr><tr><td align="left">&#x000a0;Positive</td><td char="(" align="char">79 (72.5)</td><td char="." align="char">0.79</td><td char="." align="char">0.710</td><td align="left">0.000&#x02013;3.812</td><td align="left"/><td char="." align="char">0.769</td><td char="." align="char">0.200</td><td align="left">0&#x02013;5.661</td><td align="left"/></tr><tr><td align="left">&#x000a0;Unknown</td><td char="(" align="char">11 (10.1)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">PgR status by IHC</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Negative</td><td char="(" align="char">30 (27.5)</td><td char="." align="char">1.509</td><td char="." align="char">1.396</td><td align="left">0.000&#x02013;4.738</td><td align="left"><italic>P&#x02009;</italic>&#x0003c;&#x02009;0.001*<sup>a</sup></td><td char="." align="char">1.395</td><td char="." align="char">0.628</td><td align="left">0&#x02013;12.319</td><td align="left"><italic>P&#x02009;</italic>=0.25<sup>a</sup></td></tr><tr><td align="left">&#x000a0;Positive</td><td char="(" align="char">67 (61.5)</td><td char="." align="char">0.78</td><td char="." align="char">0.672</td><td align="left">0.000&#x02013;3.812</td><td align="left"/><td char="." align="char">0.79</td><td char="." align="char">0.269</td><td align="left">0&#x02013;5.661</td><td align="left"/></tr><tr><td align="left">&#x000a0;Unknown</td><td char="(" align="char">12 (11.0)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">HER2 status by FISH</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Negative</td><td char="(" align="char">68 (62.4)</td><td char="." align="char">0.959</td><td char="." align="char">0.858</td><td align="left">0.000&#x02013;4.738</td><td align="left"><italic>P&#x02009;</italic>=&#x02009;0.21<sup>a</sup></td><td char="." align="char">1.088</td><td char="." align="char">0.305</td><td align="left">0&#x02013;12.319</td><td align="left"><italic>P&#x02009;</italic>=&#x02009;0.68<sup>a</sup></td></tr><tr><td align="left">&#x000a0;Positive</td><td char="(" align="char">22 (20.2)</td><td char="." align="char">1.121</td><td char="." align="char">1.012</td><td align="left">0.000&#x02013;4.259</td><td align="left"/><td char="." align="char">0.586</td><td char="." align="char">0.390</td><td align="left">0&#x02013;2.366</td><td align="left"/></tr><tr><td align="left">&#x000a0;Unknown</td><td char="(" align="char">19 (17.4)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr></tbody></table><table-wrap-foot><p>*Significant <italic>P</italic> values</p><p><sup>a</sup>Mann&#x02013;Whitney <italic>U</italic> test</p><p><italic>r</italic><sub><italic>s</italic></sub> Spearman rank-order correlation, <italic>ER</italic> estrogen receptor, <italic>PgR</italic> progesterone receptor, <italic>IHC</italic> immunohistochemistry, <italic>HER2</italic> human epidermal growth factor receptor 2, <italic>FISH</italic> fluorescence in situ hybridization</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec10"><title>Discussion</title><p id="Par16">Here, we showed that serum levels of sCD155 in breast cancer patients were correlated with disease stage and tumor size, suggesting that the sCD155 level in sera depends on tumor burden. These results are consistent with our previous report that sCD155 levels are higher in patients with advanced-stage gastric cancer than in those with early-stage disease and that sCD155 levels in sera are correlated with tumor size in a mouse model [<xref ref-type="bibr" rid="CR19">19</xref>]. Although there was no correlation between the expression ratio of <italic>CD155</italic>&#x003b3; in cancer tissues and the disease stage, serum levels of sCD155 and the expression ratio of <italic>CD155</italic>&#x003b3; mRNA were higher in patients with ER-negative breast cancer than in those with ER-positive cancer. These results suggest that the serum sCD155 level reflects the tumor burden, especially in ER-negative breast cancer.</p><p id="Par17">Recent studies have revealed that intrinsic subtypes of breast cancers characterized by ER-negative, PgR-negative, and HER2-negative expression (i.e., triple-negative breast cancer [TNBC]), or by ER-negative, PgR-negative, and HER2-positive expression have a poor prognosis [<xref ref-type="bibr" rid="CR22">22</xref>&#x02013;<xref ref-type="bibr" rid="CR24">24</xref>]. In addition, high expression of Ki-67 is associated with a poor prognosis for breast cancer patients [<xref ref-type="bibr" rid="CR25">25</xref>&#x02013;<xref ref-type="bibr" rid="CR27">27</xref>]. Although, in the current study, no prognostic evaluation was conducted owing to the short observation period and the small populations of TNBC and HER2-positive breast cancer, our observation of higher serum levels of sCD155 in patients with ER-negative and high Ki-67 breast cancers suggests that high levels of sCD155 in the serum might be useful for predicting poor prognosis in patients with breast cancer.</p><p id="Par18">Although we observed that sCD155 inhibited the cytotoxic activity mediated by DNAM-1 on NK cells in vitro (unpublished observation), the functional role of sCD155 in tumor immunity in vivo remains unclear. Although the activating receptor DNAM-1 and the inhibitory receptors TIGIT (T cell immunoreceptor with Ig and immunoreceptor tyrosine-based inhibitory motif domains) and CD96 are able to bind to membrane-bound CD155 [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>], it remains undetermined (a) whether these receptors can also bind to sCD155 in vivo, (b) which receptor (if any) shows higher affinity to sCD155, and (c) whether sCD155 shows either antagonistic or agonistic activity to CTL and NK cells if it binds to either receptor. These questions are important to clarify the pathophysiological role of sCD155 in tumor immunity.
</p></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>This research was supported in part by KAKENHI (grant numbers JP26861038 and JP17K10533 to AI-M; JP15H01365 and JP16H06387 to AS; and JP16H05169 to KS). We thank Drs. S. Kamikawaji, S. Kuramoto, and H. Tsunoda of Chugai Pharmaceutical Co., Ltd. for the anti-CD155 monoclonal antibodies, Dr. H. Hara for daily medical practice, N. Kato for management of serum samples, and S. Tochihara for secretarial assistance.</p></ack><notes notes-type="ethics"><title>Compliance with ethical standards</title><notes notes-type="COI-statement"><title>Conflict of interest</title><p id="Par19">The authors have no conflicts of interest for this article.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunn</surname><given-names>GP</given-names></name><name><surname>Old</surname><given-names>LJ</given-names></name><name><surname>Schreiber</surname><given-names>RD</given-names></name></person-group><article-title>The three Es of cancer immunoediting</article-title><source>Annu Rev Immunol</source><year>2004</year><volume>22</volume><fpage>329</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1146/annurev.immunol.22.012703.104803</pub-id><pub-id pub-id-type="pmid">15032581</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schreiber</surname><given-names>RD</given-names></name><name><surname>Old</surname><given-names>LJ</given-names></name><name><surname>Smyth</surname><given-names>MJ</given-names></name></person-group><article-title>Cancer immunoediting: integrating immunity&#x02019;s roles in cancer suppression and promotion</article-title><source>Science</source><year>2011</year><volume>331</volume><fpage>1565</fpage><lpage>1570</lpage><pub-id pub-id-type="doi">10.1126/science.1203486</pub-id><pub-id pub-id-type="pmid">21436444</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swann</surname><given-names>JB</given-names></name><name><surname>Smyth</surname><given-names>MJ</given-names></name></person-group><article-title>Immune surveillance of tumors</article-title><source>J Clin Invest.</source><year>2007</year><volume>117</volume><fpage>1137</fpage><lpage>1146</lpage><pub-id pub-id-type="doi">10.1172/JCI31405</pub-id><pub-id pub-id-type="pmid">17476343</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lanier</surname><given-names>LL</given-names></name></person-group><article-title>NK cell recognition</article-title><source>Annu Rev Immunol</source><year>2005</year><volume>23</volume><fpage>225</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.1146/annurev.immunol.23.021704.115526</pub-id><pub-id pub-id-type="pmid">15771571</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunn</surname><given-names>GP</given-names></name><name><surname>Koebel</surname><given-names>CM</given-names></name><name><surname>Schreiber</surname><given-names>RD</given-names></name></person-group><article-title>Interferons, immunity and cancer immunoediting</article-title><source>Nat Rev Immunol</source><year>2006</year><volume>6</volume><fpage>836</fpage><lpage>848</lpage><pub-id pub-id-type="doi">10.1038/nri1961</pub-id><pub-id pub-id-type="pmid">17063185</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shibuya</surname><given-names>A</given-names></name><name><surname>Campbell</surname><given-names>D</given-names></name><name><surname>Hannum</surname><given-names>C</given-names></name><name><surname>Yssel</surname><given-names>H</given-names></name><name><surname>Franz-Bacon</surname><given-names>K</given-names></name><name><surname>McClanahan</surname><given-names>T</given-names></name><etal/></person-group><article-title>DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes</article-title><source>Immunity</source><year>1996</year><volume>4</volume><fpage>573</fpage><lpage>581</lpage><pub-id pub-id-type="doi">10.1016/S1074-7613(00)70060-4</pub-id><pub-id pub-id-type="pmid">8673704</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kojima</surname><given-names>H</given-names></name><name><surname>Kanada</surname><given-names>H</given-names></name><name><surname>Shimizu</surname><given-names>S</given-names></name><name><surname>Kasama</surname><given-names>E</given-names></name><name><surname>Shibuya</surname><given-names>K</given-names></name><name><surname>Nakauchi</surname><given-names>H</given-names></name><etal/></person-group><article-title>CD226 mediates platelet and megakaryocytic cell adhesion to vascular endothelial cells</article-title><source>J Biol Chem</source><year>2003</year><volume>278</volume><fpage>36748</fpage><lpage>36753</lpage><pub-id pub-id-type="doi">10.1074/jbc.M300702200</pub-id><pub-id pub-id-type="pmid">12847109</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bottino</surname><given-names>C</given-names></name><name><surname>Castriconi</surname><given-names>R</given-names></name><name><surname>Pende</surname><given-names>D</given-names></name><name><surname>Rivera</surname><given-names>P</given-names></name><name><surname>Nanni</surname><given-names>M</given-names></name><name><surname>Carnemolla</surname><given-names>B</given-names></name><etal/></person-group><article-title>Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule</article-title><source>J Exp Med</source><year>2003</year><volume>198</volume><fpage>557</fpage><lpage>567</lpage><pub-id pub-id-type="doi">10.1084/jem.20030788</pub-id><pub-id pub-id-type="pmid">12913096</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tahara-Hanaoka</surname><given-names>S</given-names></name><name><surname>Shibuya</surname><given-names>K</given-names></name><name><surname>Onoda</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Yamazaki</surname><given-names>S</given-names></name><name><surname>Miyamoto</surname><given-names>A</given-names></name><etal/></person-group><article-title>Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2/CD112)</article-title><source>Int Immunol</source><year>2004</year><volume>16</volume><fpage>533</fpage><lpage>538</lpage><pub-id pub-id-type="doi">10.1093/intimm/dxh059</pub-id><pub-id pub-id-type="pmid">15039383</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tahara-Hanaoka</surname><given-names>S</given-names></name><name><surname>Miyamoto</surname><given-names>A</given-names></name><name><surname>Hara</surname><given-names>A</given-names></name><name><surname>Honda</surname><given-names>S</given-names></name><name><surname>Shibuya</surname><given-names>K</given-names></name><name><surname>Shibuya</surname><given-names>A</given-names></name></person-group><article-title>Identification and characterization of murine DNAM-1 (CD226) and its poliovirus receptor family ligands</article-title><source>Biochem Biophys Res Commun</source><year>2005</year><volume>329</volume><fpage>996</fpage><lpage>1000</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2005.02.067</pub-id><pub-id pub-id-type="pmid">15752754</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopez</surname><given-names>M</given-names></name><name><surname>Aoubala</surname><given-names>M</given-names></name><name><surname>Jordier</surname><given-names>F</given-names></name><name><surname>Isnardon</surname><given-names>D</given-names></name><name><surname>Gomez</surname><given-names>S</given-names></name><name><surname>Dubreuil</surname><given-names>P</given-names></name></person-group><article-title>The human poliovirus receptor related 2 protein is a new hematopoietic/endothelial homophilic adhesion molecule</article-title><source>Blood</source><year>1998</year><volume>92</volume><fpage>4602</fpage><lpage>4611</lpage><pub-id pub-id-type="doi">10.1182/blood.V92.12.4602</pub-id><pub-id pub-id-type="pmid">9845526</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwasaki</surname><given-names>A</given-names></name><name><surname>Welker</surname><given-names>R</given-names></name><name><surname>Mueller</surname><given-names>S</given-names></name><name><surname>Linehan</surname><given-names>M</given-names></name><name><surname>Nomoto</surname><given-names>A</given-names></name><name><surname>Wimmer</surname><given-names>E</given-names></name></person-group><article-title>Immunofluorescence analysis of poliovirus receptor expression in Peyer&#x02019;s patches of humans, primates, and CD155 transgenic mice: implications for poliovirus infection</article-title><source>J Infect Dis</source><year>2002</year><volume>186</volume><fpage>585</fpage><lpage>592</lpage><pub-id pub-id-type="doi">10.1086/342682</pub-id><pub-id pub-id-type="pmid">12195344</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masson</surname><given-names>D</given-names></name><name><surname>Jarry</surname><given-names>A</given-names></name><name><surname>Baury</surname><given-names>B</given-names></name><name><surname>Blanchardie</surname><given-names>P</given-names></name><name><surname>Laboisse</surname><given-names>C</given-names></name><name><surname>Lustenberger</surname><given-names>P</given-names></name><etal/></person-group><article-title>Overexpression of the CD155 gene in human colorectal carcinoma</article-title><source>Gut</source><year>2001</year><volume>49</volume><fpage>236</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.1136/gut.49.2.236</pub-id><pub-id pub-id-type="pmid">11454801</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carlsten</surname><given-names>M</given-names></name><name><surname>Bjorkstrom</surname><given-names>NK</given-names></name><name><surname>Norell</surname><given-names>H</given-names></name><name><surname>Bryceson</surname><given-names>Y</given-names></name><name><surname>van Hall</surname><given-names>T</given-names></name><name><surname>Baumann</surname><given-names>BC</given-names></name><etal/></person-group><article-title>DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells</article-title><source>Cancer Res</source><year>2007</year><volume>67</volume><fpage>1317</fpage><lpage>1325</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-2264</pub-id><pub-id pub-id-type="pmid">17283169</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lakshmikanth</surname><given-names>T</given-names></name><name><surname>Burke</surname><given-names>S</given-names></name><name><surname>Ali</surname><given-names>TH</given-names></name><name><surname>Kimpfler</surname><given-names>S</given-names></name><name><surname>Ursini</surname><given-names>F</given-names></name><name><surname>Ruggeri</surname><given-names>L</given-names></name><etal/></person-group><article-title>NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo</article-title><source>J Clin Invest.</source><year>2009</year><volume>119</volume><fpage>1251</fpage><lpage>1263</lpage><pub-id pub-id-type="doi">10.1172/JCI36022</pub-id><pub-id pub-id-type="pmid">19349689</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iguchi-Manaka</surname><given-names>A</given-names></name><name><surname>Kai</surname><given-names>H</given-names></name><name><surname>Yamashita</surname><given-names>Y</given-names></name><name><surname>Shibata</surname><given-names>K</given-names></name><name><surname>Tahara-Hanaoka</surname><given-names>S</given-names></name><name><surname>Honda</surname><given-names>S</given-names></name><etal/></person-group><article-title>Accelerated tumor growth in mice deficient in DNAM-1 receptor</article-title><source>J Exp Med</source><year>2008</year><volume>205</volume><fpage>2959</fpage><lpage>2964</lpage><pub-id pub-id-type="doi">10.1084/jem.20081611</pub-id><pub-id pub-id-type="pmid">19029379</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koike</surname><given-names>S</given-names></name><name><surname>Horie</surname><given-names>H</given-names></name><name><surname>Ise</surname><given-names>I</given-names></name><name><surname>Okitsu</surname><given-names>A</given-names></name><name><surname>Yoshida</surname><given-names>M</given-names></name><name><surname>Iizuka</surname><given-names>N</given-names></name><etal/></person-group><article-title>The poliovirus receptor protein is produced both as membrane-bound and secreted forms</article-title><source>EMBO J</source><year>1990</year><volume>9</volume><fpage>3217</fpage><lpage>3224</lpage><pub-id pub-id-type="doi">10.1002/j.1460-2075.1990.tb07520.x</pub-id><pub-id pub-id-type="pmid">2170108</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baury</surname><given-names>B</given-names></name><name><surname>Masson</surname><given-names>D</given-names></name><name><surname>McDermott</surname><given-names>BM</given-names><suffix>Jr</suffix></name><name><surname>Jarry</surname><given-names>A</given-names></name><name><surname>Blottiere</surname><given-names>HM</given-names></name><name><surname>Blanchardie</surname><given-names>P</given-names></name><etal/></person-group><article-title>Identification of secreted CD155 isoforms</article-title><source>Biochem Biophys Res Commun</source><year>2003</year><volume>309</volume><fpage>175</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1016/S0006-291X(03)01560-2</pub-id><pub-id pub-id-type="pmid">12943679</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iguchi-Manaka</surname><given-names>A</given-names></name><name><surname>Okumura</surname><given-names>G</given-names></name><name><surname>Kojima</surname><given-names>H</given-names></name><name><surname>Cho</surname><given-names>Y</given-names></name><name><surname>Hirochika</surname><given-names>R</given-names></name><name><surname>Bando</surname><given-names>H</given-names></name><etal/></person-group><article-title>Increased soluble CD155 in the serum of cancer patients</article-title><source>PLoS One</source><year>2016</year><volume>11</volume><fpage>e0152982</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0152982</pub-id><pub-id pub-id-type="pmid">27049654</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perou</surname><given-names>CM</given-names></name><name><surname>Sorlie</surname><given-names>T</given-names></name><name><surname>Eisen</surname><given-names>MB</given-names></name><name><surname>van de Rijn</surname><given-names>M</given-names></name><name><surname>Jeffrey</surname><given-names>SS</given-names></name><name><surname>Rees</surname><given-names>CA</given-names></name><etal/></person-group><article-title>Molecular portraits of human breast tumours</article-title><source>Nature</source><year>2000</year><volume>406</volume><fpage>747</fpage><lpage>752</lpage><pub-id pub-id-type="doi">10.1038/35021093</pub-id><pub-id pub-id-type="pmid">10963602</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldhirsch</surname><given-names>A</given-names></name><name><surname>Wood</surname><given-names>WC</given-names></name><name><surname>Coates</surname><given-names>AS</given-names></name><name><surname>Gelber</surname><given-names>RD</given-names></name><name><surname>Thurlimann</surname><given-names>B</given-names></name><name><surname>Senn</surname><given-names>HJ</given-names></name></person-group><article-title>Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011</article-title><source>Ann Oncol.</source><year>2011</year><volume>22</volume><fpage>1736</fpage><lpage>1747</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdr304</pub-id><pub-id pub-id-type="pmid">21709140</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sorlie</surname><given-names>T</given-names></name><name><surname>Perou</surname><given-names>CM</given-names></name><name><surname>Tibshirani</surname><given-names>R</given-names></name><name><surname>Aas</surname><given-names>T</given-names></name><name><surname>Geisler</surname><given-names>S</given-names></name><name><surname>Johnsen</surname><given-names>H</given-names></name><etal/></person-group><article-title>Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications</article-title><source>Proc Natl Acad Sci USA.</source><year>2001</year><volume>98</volume><fpage>10869</fpage><lpage>10874</lpage><pub-id pub-id-type="doi">10.1073/pnas.191367098</pub-id><pub-id pub-id-type="pmid">11553815</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sotiriou</surname><given-names>C</given-names></name><name><surname>Neo</surname><given-names>SY</given-names></name><name><surname>McShane</surname><given-names>LM</given-names></name><name><surname>Korn</surname><given-names>EL</given-names></name><name><surname>Long</surname><given-names>PM</given-names></name><name><surname>Jazaeri</surname><given-names>A</given-names></name><etal/></person-group><article-title>Breast cancer classification and prognosis based on gene expression profiles from a population-based study</article-title><source>Proc Natl Acad Sci USA.</source><year>2003</year><volume>100</volume><fpage>10393</fpage><lpage>10398</lpage><pub-id pub-id-type="doi">10.1073/pnas.1732912100</pub-id><pub-id pub-id-type="pmid">12917485</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carey</surname><given-names>LA</given-names></name><name><surname>Perou</surname><given-names>CM</given-names></name><name><surname>Livasy</surname><given-names>CA</given-names></name><name><surname>Dressler</surname><given-names>LG</given-names></name><name><surname>Cowan</surname><given-names>D</given-names></name><name><surname>Conway</surname><given-names>K</given-names></name><etal/></person-group><article-title>Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study</article-title><source>JAMA</source><year>2006</year><volume>295</volume><fpage>2492</fpage><lpage>2502</lpage><pub-id pub-id-type="doi">10.1001/jama.295.21.2492</pub-id><pub-id pub-id-type="pmid">16757721</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colozza</surname><given-names>M</given-names></name><name><surname>Azambuja</surname><given-names>E</given-names></name><name><surname>Cardoso</surname><given-names>F</given-names></name><name><surname>Sotiriou</surname><given-names>C</given-names></name><name><surname>Larsimont</surname><given-names>D</given-names></name><name><surname>Piccart</surname><given-names>MJ</given-names></name></person-group><article-title>Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?</article-title><source>Ann Oncol</source><year>2005</year><volume>16</volume><fpage>1723</fpage><lpage>1739</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdi352</pub-id><pub-id pub-id-type="pmid">15980158</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Azambuja</surname><given-names>E</given-names></name><name><surname>Cardoso</surname><given-names>F</given-names></name><name><surname>de Castro</surname><given-names>G</given-names></name><name><surname>Colozza</surname><given-names>M</given-names></name><name><surname>Mano</surname><given-names>MS</given-names></name><name><surname>Durbecq</surname><given-names>V</given-names></name><etal/></person-group><article-title>Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients</article-title><source>Br J Cancer</source><year>2007</year><volume>96</volume><fpage>1504</fpage><lpage>1513</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6603756</pub-id><pub-id pub-id-type="pmid">17453008</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yerushalmi</surname><given-names>R</given-names></name><name><surname>Woods</surname><given-names>R</given-names></name><name><surname>Ravdin</surname><given-names>PM</given-names></name><name><surname>Hayes</surname><given-names>MM</given-names></name><name><surname>Gelmon</surname><given-names>KA</given-names></name></person-group><article-title>Ki67 in breast cancer: prognostic and predictive potential</article-title><source>Lancet Oncol.</source><year>2010</year><volume>11</volume><fpage>174</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(09)70262-1</pub-id><pub-id pub-id-type="pmid">20152769</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Harden</surname><given-names>K</given-names></name><name><surname>Gonzalez</surname><given-names>LC</given-names></name><name><surname>Francesco</surname><given-names>M</given-names></name><name><surname>Chiang</surname><given-names>E</given-names></name><name><surname>Irving</surname><given-names>B</given-names></name><etal/></person-group><article-title>The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells</article-title><source>Nat Immunol</source><year>2009</year><volume>10</volume><fpage>48</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1038/ni.1674</pub-id><pub-id pub-id-type="pmid">19011627</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuchs</surname><given-names>A</given-names></name><name><surname>Cella</surname><given-names>M</given-names></name><name><surname>Giurisato</surname><given-names>E</given-names></name><name><surname>Shaw</surname><given-names>AS</given-names></name><name><surname>Colonna</surname><given-names>M</given-names></name></person-group><article-title>Cutting edge: CD96 (tactile) promotes NK cell-target cell adhesion by interacting with the poliovirus receptor (CD155)</article-title><source>J Immunol.</source><year>2004</year><volume>172</volume><fpage>3994</fpage><lpage>3998</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.172.7.3994</pub-id><pub-id pub-id-type="pmid">15034010</pub-id></element-citation></ref></ref-list></back></article>